Source: Eur Respir J 2011; 37: 974



Rating:

Share or cite this content

Citations should be made in the following way:
Mohapatra P.R., Hari D.T.. Predicting outcomes and drug resistance with new standardised treatment. Eur Respir J 2011; 37: 974

Member's Comments

No comment yet.

Related content which might interest you: Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Source: Eur Respir J 2010; 36: 870-877 Year: 2010 Impact of drug resistance among new cases on outcome of DOTS category I Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance Source: Eur Respir J 2014; 43: 566-581 Year: 2013 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 A Cuban successful history on antituberculosis treatment and drug resistance surveillance Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 569-571 Year: 2015 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 571-574 Year: 2015 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Factors preventing better treatment completion among MDR TB cases in a rich-resource setting Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003 MDR/XDR-TB treatment outcome Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Stewardship programmes to decrease antibiotic resistance and to improve outcomes Source: International Congress 2018 – New Sepsis Surviving Campaign guidelines: back to the “art of medicine” Year: 2018 SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2-agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020